univers coverag
calendar event
pdufa burosumab xlh fda adcom brief document peripher
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
medic meet american societi cataract refract surgeri american
associ cancer research arql interphex annual meet
rx chain
bottom line perspect see dual prong news flow
unlik enter hospit drug suppli chain presid trump pois
give speech drug price suppli chain reform april hh secretari azar
solicit idea price reform posit drug suppli chain across pbm drug
distributor biopharma manufactur roil fear margin compress
threat within coverag view posit optum rx pbm ci
deal acquir esrx aet ink deal part equiti well
ingeniorx without potenti deal sizabl mail order
per cnbc news flow view challeng larg scale suppli hospit logist
associ drug deliveri meaning rule entri drug suppli chain
cnbc announc link enter hospit drug suppli chain given challeng
larg scale deliveri logist pharmaceut deliveri bode posit biopharma manufactur
drug suppli chain
similarli news presid donald trump pois offer speech drug price reform
april link secretari solicit idea drug price reform also suggest regulatori fear
associ pbm busi model overblown
fact secretari link press releas even fda commission scott gottlieb recent
cnbc healthi return confer publicli laud move unitedhealthcar point sale
po drug discount worker share rebat drug manufactur follow
aet
perspect also see transpar busi model align
issu within stand-alon pbm like address larg vertic deal within regul
highli competit umbrella specul ink deal close new
bottom line american associ cancer research meet present
preclin data engin strain syn-st syn-kyn syn-ad exploit differ
anti-tumor target fight cancer earli result begin expand potenti reach synthet
biotic medicin beyond compani lead focu rare diseas know
program advanc plan bring first immuno-oncolog io candid ind-en
studi success program present upsid includ io revenu
compani model reiter op
syn-st stimul interferon gene turn cold tumor infiltr hot tumor expand
previou preclin data expand promis synthet biotic io
syn-kyn syn-ad strain could exploit addit anti-tumor target synergist
plan advanc first candid ind-en studi upsid current valuat
leadership agil largest busi transit expect new appt
bottom line market close today agil announc patrick kaltenbach senior vice-president
presid agil largest divis lsag life scienc appli market group
leav end week lsag account almost agil revenu though news
come surpris us believ kaltenbach departur pure voluntari expect
join direct competitor ceo mcmullen expect name new leader shortli high likelihood
posit fill someon intern agil rather extern candid patrick
kaltenbach deepli miss given extens industri background agil span
year join hewlett packard engin rose rank
becom presid lsag number product convers patrick given deep
industri knowledg instrument root
kaltenbach instrument launch agil new instrument product portfolio
believ news came surpris agil manag well kaltenbach decis
bottom line today publish quarterli preview larg cap biopharma
compani coverag analysi im sale prescript data product specif price
chang currenc chang consid updat revenu earn forecast
model base updat analysi effect currenc price channel inventori
underli demand appear us compani larg cap biotechnolog univers
report surprisingli strong result report signific beat compar consensu
across coverag celgen seem risk fall short expect
gilead vertex seem like beat consensu revenu earn among blockbust
medicin within coverag univers find humira like beat consensu estim
revlimid risk fall short
tradit particularli strong quarter manufactur specialti biopharmaceut
revenu mm dilut ep includ option expens present
revenu mm ep exclud option expens
revenu million dilut non-gaap ep
revenu ep exclud option expens estim pro forma spin
revenu million ep exclud option expens
revenu mm non-gaap ep ex stock option expens
revenu mm dilut ep non-gaap
first vasostrict anda file come surpris
bottom line morn announ abbrevi new drug
applic anda vasopressin inject submit accept file
fda press releas state product gener version endo origin
vasostrict formul indic increas blood pressur adult vasodilatori shock
remain hypotens despit fluid catecholamin long time believ
matter gener would come margin earliest eagl
gener could get approv appear late assumpt
surpris eventu gener entri point past date difficult know
exactli might believ investor like assum worst case scenario
vasostrict first anda file known competit threat vasostrict
compound version appear less like given recent fda commentari guidanc
believ increas clariti around durabl asset would support
stock potenti weak respons today headlin
bottom line cnbc report afternoon amazon shelv plan enter
pharmaceut suppli chain cite insid cnbc report compani run
challeng suppli hospit bulk shipment logist need handl pharma
deliveri cnbc articl report focus sell less sensit medic suppli
hospit smaller clinic consist previous publish work link
link challeng incur amazon suppli larg hospit health system
also consist work recent survey link show unlik
amazon would abl captur signific share tradit distributor
distribut relationship impact mani factor price convers kol
consist highlight mani hurdl healthcar distribut
exist relationship loyalti trust remain import factor amazon press
paus pharma ambit discuss former senior execut amazon
suggest decis enter new market made annual basi team may
continu work market explor even formal decis enter link
data secur breach manag guidanc rais like may
weekli iqvia im trend week end april
new fda along monograph could present oppi over-the-counter growth
like posit catalyst conserv guidanc estim
selonsertib quietli goe awri easl may risk
averag price-to-earnings large-cap revenu multipl slower-growth medic co sum part exist
franchis dcf
btki data still earli akti data look encourag
 like posit catalyst conserv guidanc
medic suppli devic individu co preview ortho supplies/cap equipment/
medic suppli devic individu co preview cardio large-cap diversifi
burosumab recent receiv posit eu chmp decis x-link hypophosphatemia
xlh believ encourag
burosumab adult xlh pt demonstr continu stabil serum phosphoru
level improv secondari endpoint stiff physic function pain
addit possibl disease-modifi characterist improv bone health
posit chmp decis provid credenc favor top-lin ph data initi
fda advisori committe meet expect
storm phase ii studi selinexor penta-refractori multipl myeloma mm
full interim storm result selinexor low-dos dexamethason dex first
patient highlight drug single-ag activ difficult-to-treat patient --
management believ bode well approv probabl drug
prior data indic solid activ orr overal respons rate across
variou subgroup quad penta-refractori pt
expans cohort addit penta-refractori mm patient expect
top-lin data orr primari endpoint end april
believ selinexor could potenti address peak us sale opportun
risk-adjust multipl myeloma
event posit data manag plan submit nda
may genesight data present pharmacogenom test
believ data present american psychiatr associ confer
provid insight secondari genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
may dova pdufa avathombopag thrombocytopenia chronic liver
fda accept avatrombopag nda prioriti review treatment
thrombocytopenia patient chronic liver diseas cld schedul undergo
presum regul valid dova high degre confid
approv applic basi trial well studi
conduct indic
compani plan immedi launch june approv begun hire
key sale staff includ head us sale deep experi liver diseas drug
dova also remain track complet regulatori submiss ema approv
indic
addit cld indic dova explor label expans opportun broader
pre-surgeri popul thrombocytopenia patient chemotherapy-induc
dova believ opportun tripl size avatrombopag address market
june american societi clinic oncolog
year updat patient treat combin lead
candid mirvetuximab soravtansin avastin
result includ data dose-expans cohort -- patient
avastin-na previous receiv avastin
line treatment set avastin-na pt avastin previous gener
median progression-fre surviv mpf chemotherapi well
expect topic jak inhibitor ph ii top-lin data alopecia areata
aa us studi patient one month durat could demonstr
earli valid topic jak inhibitor approach
also develop topic jak janu kinas inhibitor patchi hair loss
possibl androgenet alopecia aga aka male/femal pattern bald
success would open anoth multi-billion dollar market
compani jak inhibitor program treatment immune-medi hair loss
disord aa core upsid driver model account
even use conserv assumpt believ oral jak inhibitor could achiev peak
annual sale aa alon
ph ii top-lin data australia eyebrow studi patient
view agent novel chemic structur avoid format presum toxic
metabolit good reason atogep could avoid liver toxic seen
telcagep follow-on compound
support view gen molecul calcitonin gene-rel peptid cgrp
may avoid liver safeti risk management report un-blind look liver enzym
elev agn on-going atogep studi line placebo event rate
clinic studi
atogep deliv efficaci profil within strike distanc inject
good safeti toler work suggest sizabl market opportun base
inject categori oral late entrant xeljanz rheumatoid arthriti otezla
psoriasi
believ program good chanc success view success
atogep migrain prevent would offer signific valid agn open-sci
bold ph i/ii x-link myotubular myopathy/xlmtm
audent expect announc updat phase i/ii aspiro data
possibl american societi gene cell therapi confer may
also expect phase i/ii valen data possibl european societi
pediatr gastroenterolog hepatolog nutrit meet may
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
scph lead asset furoscix at-hom diuresi anticip pdufa action date
manag see signific opportun furoscix reduc patient admiss day
hospit acceler patient discharg reduc readmiss rate
continu believ furoscix subcutan administr gain strong earli
adopt hospital-bas event drive iv furosemid use market
iv diuresi iv furosemid
believ furoscix provid strong pharmacoeconom incent move care
high cost hospit set at-hom set
continu see odd success approv forecast
sale sale
initi furoscix heart failur health econom outcom research studi
june akao pdufa plazomicin gram neg infect
decemb akao report posit top-lin data two phase studi epic
expect support registr expect primari driver
commerci adopt
epic recruit patient suspect complic urinari tract infect cuti
demonstr plazomicin statist non-inferior meropenem fda primari
endpoint statist superior three key efficaci measur includ ema
primari outcom test cure
see nich role plazo treatment-refractori cuti expect drug
primari clinic util carbapenem-resist enterobacteriacea support
compel data studi albeit small sampl show
reduct death/seri complic mortal respect rel
activ control
continu project peak sale plazomicin ww us sale
row royalti us sale come
fda adcom meet may believ like vote
approv plazomicin along indic bloodstream infect caus certain
sourc leerink research compani inform factset price prior day
fda adcom brief document peripher central nervou system drug
fda adcom peripher central nervou system drug
fda adcom arthriti drug safeti risk manag
fda adcom brief document antimicrobi drug plazomicin akao
fda adcom brief document gastrointestin drug pediatr
fda adcom antimicrobi drug plazomicin akao
fda adcom gastrointestin drug pediatr stannsoporfin infect
fda adcom endocrinolog metabol drug
pdufa dova avatrombopag thrombocytopenia chronic liver diseas
pdufa akao plazomicin complic urinari tract infect bloodstream
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
american societi cataract refract surgeri
american associ cancer research arql
american head neck societi combin otolaryngolog spring meet
american societi androlog
european congress clinic microbiolog infecti diseas
american academi neurolog
nation foundat infecti diseas annual confer vaccin
american societi aesthet plastic surgeri
american congress obstetrician gynecologist
american associ neurolog surgeon
american associ thorac surgeri
american colleg occup environment medicin
associ research vision ophthalmolog nite
american societi pediatr hematology/oncolog
intern societi cellular therapi
american societi breast surgeon
american associ immunologist
pan american societi clinic virolog
european societi pediatr gastroenterolog hepatolog nutrit
societi biolog psychiatri
societi pediatr radiolog
abstract releas edt
societi investig dermatolog
american societi gene cell therapi
american associ clinic endocrinologist
model univers coverag
 like posit catalyst conserv guidanc
medic suppli devic individu co preview ortho supplies/cap equipment/
medic suppli devic individu co preview cardio large-cap diversifi
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst market
 aducanumab titrat arm bolster evid treatment effect market perform
 ctad medacorp call aducanumab abeta hypothesi
life scienc tool diagnost -- flash fund present posit upsid nih
spend life scienc tool
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt market
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
 ttr seri part handicap on-going tafamidi trial fac market
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma praluent show mortal benefit lower take aim highest risk group
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo rewind
biopharma -- flash highlight invokana fda warn puls call modest impact
 leerink confer highlight dinner manag market
 model updat reflect goal achiev w/ pipelin success market
mdco -- flash inclisiran lesson fourier/odyssey may better
mdco anoth step forward cubist vabomer approv pt outperform
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
biopharma -- flash highlight invokana fda warn puls call modest impact
medic suppli devic abt/mdt secur approv diabet devic
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
novob dc -- flash near-unanim vote clear path semaglutid approv
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market perform
esrx aggress price loss competit market pt market perform
hcit distribut brand inflat top show deceler y/i
cautiou
hcit distribut fda take step improv competit distributor near trough
 respit price yet friendli hill fda could
biopharma name shame california latest strategi rein drug price
healthcar distribut suppli chain preview price volum trend appear
hcit distribut outlin possibl drug price polici draconian
fear
 elast demand consist reduc price drive volum growth
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
 deep dive highlight oncolog focu strategi nash market perform
 patent fall hurdl humira cut like pipelin loom market
achn recap increment advanc patent complement progress
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win market
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year outperform
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
biopharma might deton event look like screen pot match-
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 management highlight robust partnership program pt
 add cscc respons diseas boost /sni partnership
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
 atop dermat still without ped leerink dupix
derm survey
 hiv survey rapid adopt biktarvi challeng outlook
gsk
 initi
hcit distribut hospit hcit survey highlight shift analyt
moat vs
medic suppli devic survey direct posit
mute hope new indications/improv execut
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
major highlight medacorp lung cancer survey focus
nsclc
 initi could adenosin inhibit unlock wave i/o
outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
 pnh survey-soliri still grow like switch monthli sc best
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
 rubraca posit base survey lower est due payer assist
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
 physician survey support nerlynx opp ty breast cancer pt
medic devic survey direct posit mute hope
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leerink leadership seri new product growth acceler stori market
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devices-cardiolog leerink leadership seri target
outlook alpha opportun abound healthcar share
